Back
Speaker illustration

undefined undefined undefined

Presentations

Valsartan reduces level of soluble ST2 and left ventricle remodeling in patients with dual chamber pacemaker

Event: ESC Congress 2019

Topic: Treatment

Session: Treatment of the chronic heart failure

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources